| | Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer |
|
| Catalent has reached an agreement to acquire Bettera Holdings, LLC, a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market. |
|
| Bettera will complement and accelerate the growth of Catalent’s global softgel and oral dose formulation and manufacturing business to provide consumer health innovators with unrivalled choice, formulation expertise, and high-quality, scalable manufacturing solutions to help bring new products to market. |
|
| | | Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals |
|
| Catalent will undertake the commercial manufacturing and packaging of Phathom Pharmaceuticals’ lead compound, vonoprazan, a novel, orally active-potassium competitive acid blocker (P-CAB), at its large -scale oral solid dose manufacturing site in Winchester, Kentucky. | | Read the Release |
|
| | | Catalent’s Chair and CEO, John Chiminski Interviewed by Fox Business Network
John Chiminski, Catalent's Chair and CEO, discussed manufacturing COVID-19 vaccines for Moderna, Johnson & Johnson and AstraZeneca. He describes how Catalent overcame supply chain challenges at the height of the pandemic. Watch the clip.
Catalent has been awarded more than 80 COVID-19-related compounds, and is on track to deliver over one billion COVID-19 vaccine and treatment doses this year. |
|
| | | | | Growth of mRNA Discussed by Catalent Experts in Pharma Manufacturing
Catalent’s Matt Blume, Vice President of Business Transformation in Clinical Supply Services and Stacey Treichler, Ph.D., Associate Director of Marketing, Biotherapeutics, discuss the growth of one of the industry’s most talked about innovations, mRNA technology. | | Read the Article | | |
|
| Catalent Expert Discusses Dosage Form Design in Pharmaceutical Technology
William Chin, Ph.D., Catalent’s Global Scientific Affairs Manager, discusses the ways dosage form priorities are shifting to focus on user-friendliness in Pharmaceutical Technology. | | Read the Article |
|
| Upcoming Events: Join Our Experts to Hear the Latest on Technology Development Programs |
|
| | | | | Cell & Gene Therapy
Cell & Gene Therapy Manufacturing and Commercialization | Boston | September 20 - 23
Join us on September 21, 2021, to hear Catalent expert, Nagendra Singh, Senior Scientist, Downstream Process Development, Catalent Cell & Gene Therapy, give an insightful presentation titled, “Evaluation of Novel Affinity Resin with Alkali Stable Ligand for AAV Viral Vectors”.
Knowledge for Growth | Ghent, Belgium | September 27 – 29 Within the “Personalized Medicine” track, Dr. Pinxteren will join the “Beyond the Science” panel session on Tuesday, 28th September at 3:30 p.m. CET.
Cell Gene Meeting on the Mesa | Carlsbad, California & Virtual | October 12-14
Meet Catalent’s Cell & Gene Therapy team online in our virtual booth at Meeting on the Mesa. Schedule a meeting to discuss your current or future AAV, CAR-T, lentiviral or other advanced therapeutic projects and learn how our expertise can help bring your lifechanging treatment to patients. |
Clinical Supply Services
GCSG 2021 European Virtual Knowledge Forum | Virtual | October 5-7
Catalent is delighted to be sponsoring and exhibiting at this year’s event. Our experts will be available to connect and participate in networking events throughout the course of this forum. Learn more and schedule a meeting with our team today!
Consumer Health
Webinar | The Growth of Premium in Nutritional Supplements | September 27 Experts discuss several new advanced delivery technologies that can help differentiate your premium supplement as you look to continue your brand’s growth.
Webinar | How Unit Dose Beauty Is Reshaping the Beauty Market | September 30
When it comes to certain ingredients and types of beauty products, conserving the potency is key to keeping products at their full potential. As we think of how the beauty market has evolved and started adopting to new trends, there is a huge opportunity for unit dose delivery systems, such as capsules and ampoules, to accelerate beyond the high success it has today.
Vitafoods Europe | Geneva, Switzerland | October 5-7
Learn more about Catalent’s development and manufacturing capabilities for consumer health products, including about our proposed acquisition of Bettera. Schedule a meeting with our experts or drop in on our booth E103 at Vitafoods Europe.
SupplySide West | Las Vegas | October 25-28
Visit Catalent’s experts in booth 2839. Schedule a meeting to learn more about our move into the growing market for gummies as well as other latest product offerings in the consumer health space. |
|
| Oral Drug Delivery
Webinar | Scale Up & Tech Transfer of Fluid-Bed Coating Processes | September 21
This webinar will summarize the principles of top-spray and bottom-spray coating using the fluidized bed platform, and will then discuss ways of selecting the most appropriate technique to meet the target product profile. Experts will also cover the scale up approach of multiparticulate coating using the fluid-bed platform as a strategy to achieve a modified release drug product.
Cannabinoid-Derived Pharmaceuticals Summit | Boston | September 21 - 23
Want to learn more about our latest developments and capabilities in oral technologies and manufacturing? Connect with our Catalent experts in Boston who will be available to assist you with your next challenge. David Fulper, Ph.D., Director, Science & Technology, Catalent will present “Exploring the Oral Delivery of Cannabinoids: Challenges, Approaches, and Solutions”.
European Paediatric Formulation Initiative (EuPFI) | Virtual | September 22 - 23
Catalent is excited to participate at this year’s EuPFI 2021. Register now and visit our virtual booth or schedule a meeting with our experts to learn more about Catalent’s latest innovations in oral technologies.
Webinar | A Guide to Drug Development of Challenging Molecules | September 23
Experts will discuss some of the key considerations, strategies, and solutions available in the drug development of challenging molecules.
Making Pharmaceuticals UK | Coventry, U.K. | October 5-6 Matt Ling, Ph.D., Director of Scientific Services, Catalent will present “Overcoming Key Challenges in Early Oral Formulation Development”
Webinar | Concept to Dosing: Challenges in New Orphan Drugs | October 6
A group of experienced cancer drug developers to discuss key strategies in managing an orphan drug program. Matthew Mollan, Ph.D., Regional Head of Operations at Catalent, will review the developability challenges of orphan oncology drugs and provide recommendations for innovator companies to consider in order to avoid common pitfalls during scale-up.
Webinar | Maintaining Drug Product Properties and Optimizing Late-Stage Manufacturing Efficiency | October 14
Register for this webinar to hear experts share approaches on how to minimize burdens often faced in the transition from early phase to late phase of a small molecule program.
Webinar | Highly Potent API Drug Product Development and Manufacturing Using Micronization Technology | October 12
This webinar will discuss how to classify HPAPIs in early development and share recommendations for safe product handling, from clinical manufacturing to commercialization. |
|
| A Catalyst in Drug Development |
|
| Elaine Villalobos
Supervisor Technical Services, Sorocaba, Brazil |
|
| In her role at Catalent, Ms. Villalobos relentlessly develops her technical services team in Sorocaba and Indaiatuba to be more agile at transferring and maintaining reliable manufacturing processes. She has a wide range of experience in dosage forms in softgels, creams and tablets. Learn a little more about Ms. Villalobos’ role and discover some of her techniques for troubleshooting tech transfers and the ways her team helps drive Catalent’s ‘Patient First’ mission. |
|
|
|
| | | | | | | | Biologics Development and Manufacturing Explore the world-class late-stage and commercial manufacturing for vial fill/finish and secondary packaging of biologics and sterile products in this 360° virtual tour of Catalent’s facility in Anagni, Italy. | | | Consumer Health In this 360° virtual tour, explore our facility in Windsor, Ontario, one of two sites located in Canada offering softgel development and manufacturing capabilities for the Pharmaceutical and Consumer Health industries. |
|
| | | Oral Development and Manufacturing In this 360° virtual tour explore the capabilities located at Catalent’s Winchester, Kentucky, facility, home to Catalent’s flagship U.S. manufacturing location for large scale complex-controlled release oral dose forms. |
| We are the Catalyst for your success. Join us! |
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana; Madison, Wisconsin; Harmans, Maryland; Kansas City, Missouri; and across Europe.
Visit www.catalent.com/careers for more information. |
|
| | |
|
Every brand has a challenge. We have a solution. |
|
| | | or call +1 877 891 9609 to speak with one of our experts today! |
|
| | |
|
To unsubscribe or manage your subscriptions, please click here. For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at [email protected], or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2021, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
